Dyadic International, Inc.

Good evening and welcome to the Dyadic International First Quarter 2025 Financial Results Conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this call is being recorded today, May 14, 2025. I would now like to turn the call over to Ms. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.

Thank you, good evening, and welcome everyone to Diatics International's Q1 2025 conference call. I hope you have had the opportunity to review Diatics' press release announcing financial results for the physical year-ended March 31, 2025. You may access our release and form 10-Q under the Investors section of the company's website, idiatics.com. On today's call, our President and CEO, Mark Emelfarb, And our Chief Operating Officer, Joe Hazelton, will give a review of our Q1 2025 business and corporate highlights and provide a commentary on the strategic direction of the business. I will follow with a review of our financial results in more detail. We'll then hold a brief Q&A session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements. which involve risks and uncertainties and other factors that could cause dietics as a result, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Diatics expressly disclaim any duty to provide updates to its forward-looking statements, whether because of new information, future events, or otherwise. Participants are directed to risk factors set forth in DIATIC's reports filed with the SEC. It is now my pleasure to pass the call to our CEO, Mark Emelfar. Mark?

Thank you, Ping. Welcome, everyone, and thank you for joining DIATIC's Q1 2025 conference call. In Q1 2025, DIATIC continued its transformation by focusing on commercializing high-value, high-demand recombinant enzymes and proteins using our proprietary C1 and epibis microbial expression platforms for the development of functional recombinant solutions and proprietary production strains to manufacture large quantities of precision-engineered proteins and enzymes for use in life science, nutrition, and industrial applications. We are leaning into our core strengths aimed at driving sustainable growth in non-pharmaceutical sectors with strong demand and clear market opportunities to target pressing market needs. While we maintain strategic partnerships in vaccine therapeutic developments, such as with the Coalition for Epidemic Preparedness, CEPI, the Gates Foundation, and Fondatione Biotech Napolo di Siena, FBS, the core of our growth strategy is now centered on products, in the high-value life sciences, bioactives, ingredients in industrial markets such as cell culture, media, nucleic, and other enzyme markets that can drive recurring revenue. As we move forward, DIAC remains deeply committed to delivering sustainable value to our shareholders and partners. With a growing pipeline, a strong network of collaborators, and platforms built for efficiency and scalability, We are well positioned to lead in the global production of enzymes, alternative proteins, and biopharmaceuticals meeting the demands of today and shaping the solutions of tomorrow. I will now turn the call over to Joe Hazelton, our Chief Operating Officer, who will provide you with an update on our Q1 progress towards exploiting commercialization opportunities. Joe?